{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "Eribulin Mesylate is a generic prescription drug used intravenously to treat certain cancers. It's a microtubule inhibitor that comes as a solution in single-dose vials (0.5 mg/mL strength). Manufactured by Hikma Pharmaceuticals USA Inc., it's approved under ANDA 218281. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Eribulin mesylate \u2014 ANDA 201532 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201532", "mediaType": "text/html", "title": "Eribulin mesylate"}], "identifier": "ANDA201532", "issued": "2016-09-16", "keyword": ["fda", "drug", "public-health", "health-care", "drug-information"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Eribulin mesylate"}